DUBLIN–(BUSINESS WIRE)–The “Non-Alcoholic Steatohepatitis (NASH) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This disease pipeline guide provides an overview of the Non-Alcoholic Steatohepatitis (Gastrointestinal) pipeline landscape.
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 62, 51, 1, 8, 175, 70 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 7 and 1 molecules, respectively.
Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis. (Read more…)
- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (Gastrointestinal)
Key Topics Covered:
- Non-Alcoholic Steatohepatitis (NASH) – Overview
- Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Development
- Non-Alcoholic Steatohepatitis (NASH) – Therapeutics Assessment
- Non-Alcoholic Steatohepatitis (NASH) – Companies Involved in Therapeutics Development
- Non-Alcoholic Steatohepatitis (NASH) – Drug Profiles
- Non-Alcoholic Steatohepatitis (NASH) – Dormant Projects
- Non-Alcoholic Steatohepatitis (NASH) – Discontinued Products
- Non-Alcoholic Steatohepatitis (NASH) – Product Development Milestones
Companies Mentioned
- 89bio Inc
- ABIONYX Pharma SA
- Abivax SA
- Abliva AB
- Acquist Therapeutics
- AdAlta Ltd
- Afimmune Biopharma Ltd
- Akero Therapeutics Inc
- Albireo Pharma Inc
- Aldeyra Therapeutics Inc
- Ascletis Pharma Inc
- Asdera LLC
- Assembly Biosciences Inc
- AstraZeneca Plc
- Auransa Inc
- Avaliv Therapeutics Inc
- Avolynt Inc
- ChemoCentryx Inc
- ChemomAb Ltd
- Dicerna Pharmaceuticals Inc
- Dr. Falk Pharma GmbH
- DURECT Corp
- Eli Lilly and Co
- Enanta Pharmaceuticals Inc
- EncuraGen Inc
- Engitix Ltd
- Hepion Pharmaceuticals Inc
- Heprotech Inc
- Hinova Pharmaceuticals Inc
- HK inno.N Corp
- HotSpot Therapeutics Inc
- Ildong Pharmaceutical Co Ltd
- Imago Pharmaceuticals Inc
- ImmuneMed Inc
- Immupharma Plc
- Immuron Ltd
- Indalo Therapeutics Inc
- Inmune Bio Inc
- Innovimmune Biotherapeutics Inc
- Inorbit Therapeutics AB
- Integral Molecular Inc
- Intercept Pharmaceuticals Inc
- INVENT Pharmaceuticals Inc
- InventisBio Inc
- Inventiva
- LG Chem Ltd
- LifeMax Laboratories Inc
- Liminal BioSciences Inc
- Lin Bioscience Inc
- Lipidio Pharmaceuticals Inc
- Lipocine Inc
- LISCure Biosciences Co Ltd
- Metabolys SAS
- Metacrine Inc
- MetiMedi Pharmaceuticals Co Ltd
- Micelle BioPharma Inc
- Palo BioFarma SL
- Pattern Therapeutics
- PegBio Co Ltd
- Pfizer Inc
- pH Pharma Co Ltd
- Pharmaxis Ltd
- Phenex Pharmaceuticals AG
- Pliant Therapeutics Inc
- Poxel SA
- Promethera Biosciences SA
- Protalix BioTherapeutics Inc
- Proterris Inc
- Protheragen Inc
- PTC Therapeutics Inc
- RadBio
- Redx Pharma Plc
- Regenasome Pty Ltd
- Regulus Therapeutics Inc
- Rejuvenation Technologies Inc
- reMYND NV
- Revive Therapeutics Ltd
- Rhamnopharma Inc
- Sirnaomics Inc
- SparkBioPharma Inc
- SteroTherapeutics LLC
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Sveikatal Inc
- Synlogic Inc
- T3D Therapeutics Inc
- TaiwanJ Pharmaceuticals Co Ltd
- Terns Pharmaceuticals Inc
- TES Pharma SRL
- Theratechnologies Inc
- Thetis Pharmaceuticals LLC
- Thoth Science Inc
- Wave Life Sciences Ltd
- Xenexus Pharmaceuticals Pty Ltd
- Xfibra Inc
- XORTX Therapeutics Inc
- YD Life Science Co
- Yuhan Corp
- Zebra Discovery Ltd
-
Zhejiang Doer Biologics Corp
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ohjctd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900